Skip to main content


Selected Publications

View all Johnson S publications in the NIH PubMed Database

Johnson SB, King AJ, Warner EL, Aneja S, Kann BH, Bylund CL (2023). Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information. JNCI Cancer Speclr, 7(2).

Johnson SB, Bylund CL. Identifying Cancer Treatment Misinformation and Strategies to Mitigate Its Effects with Improved Radiation Oncologist-Patient Communication. (Epub ahead of print). Pract Radiat Oncol.

Peterson J, Wilson TF, Watt MH, Gruhl J, Davis S, Olsen J, Parsons MW, Kann BH, Swire-Thompson B, Fagerlin A, Warner EL, King AJ, Chino F, Johnson SB (2023). International medical tourism of US cancer patients for alternative cancer treatments: Financial, demographic, and clinical profiles of online crowdfunding campaigns. (Epub ahead of print). Cancer Med.

Bylund CL, Mullis MD, Alpert J, Markham MJ, Onega T, Fisher CL, Johnson SB (2023). Clinician Communication with Patients About Cancer Misinformation: A Qualitative Study. (Epub ahead of print) JCO Oneal Pracl, OP2200526.

Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao R (2022). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leuk Lymphoma, 64(2), 1-8.

Peterson JS, Plana D, Bitterman DS, Johnson SB, Aerts HJWL, Kann BH (2022). Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCl)-affiliated clinical trials. (Epub ahead of print). Cancer Med.

Katherine L. Ford, Camila E. Orsso, Nicole Kiss, Skyler B. Johnson, Sarah A. Purcell, Adele Gagnon, Alessandro Laviano, Carla M. Prado. Dietary choices after a cancer diagnosis: A narrative review. Nutrition. (2022): V103-104, 111838.

Christopher R. Weil, Matthew J. Parsons, Ryan J. Hutten, Felicia H. Lew, Skyler B. Johnson, David K. Gaffney & Randa Tao (2022). Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy, Leukemia & Lymphoma

E. L. Warner & Skyler B. Johnson (2022). Fellows Can Join the Fight Against Cancer Misinformation Online. Oncology Fellows, 14(2).

Ryan J. Hutten, Geoff Nelson, Vikren Sarkar, Skyler B. Johnson, Randa Tao, Ying Hitchcock, Jessica Chan, Joyce Schroeder, Kristine Kokeny. Feasibility and Clinical Utility of a Workflow Interfacing Radiation Oncology Lung Stereotactic Body Radiation Therapy Treatment Planning and Diagnostic Radiology. Practical Radiation Oncology. 2022: V12(6), e512-e516.

Peterson J, Wilson T, Gruhl J, Davis S, Olsen J, Parsons M, Kann B, Fagerlin A, Watt M, Johnson S. Timing and Motivations for Alternative Cancer Therapy with Insights from a Crowdfunding Platform: Cross-sectional Mixed Methods Study. JMIR Cancer. 2022;8(2): e34183.

Zachary A. Seymour, Stephanie Daignault-Newton, P.W. McLaughlin, Howard Sandler, William Jackson, Skyler B. Johnson, David Miller, John Wei, Martin Sanda, Daniel A. Hamstra. Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. Clinical and Translational Radiation Oncology, 2022: V36: 56-62.

Christopher R. Weil, Ryan J. Hutten, Brandon M. Barney, Angela Fagerlin, David K. Gaffney, David Michael Gill, Gary Whipple, Terence Duane Rhodes, Laura Scherer, Gita Suneja, Jonathan David Tward, Theresa Louise Werner, Skyler B Johnson, and Jaden D. Evans. Shifting perceptions of alternative therapies in cancer patients during the COVID-19 pandemic: Results from the Complementary and Alternative Medicine Exposure in Oncology (CAMEO) Study. Journal of Clinical Oncology. (June 2022): 40:16_suppl, e24130-e24130.

Ryan J. Hutten, Christopher R. Weil, Brandon M. Barney, Angela Fagerlin, David K. Gaffney, David Michael Gill, Gary Whipple, Terence Duane Rhodes, Laura Scherer, Gita Suneja, Jonathan David Tward, Theresa Louise Werner, Jaden Evans, and Skyler B Johnson. Complementary and alternative medicine exposure in oncology (CAMEO) study: A multi-institutional cross-sectional analysis of patients receiving cancer treatment. Journal of Clinical Oncology. (2022): 40:16_suppl, e18739-e18739

Samantha Greenberg, Elizabeth Orlando, Morgan Devlin, Sara Low, Amanda Anson, Brock O Neil, Wendy Kohlmann, Bob Wong, Christopher B. Dechet, Alejandro Sanchez, Jonathan David Tward, Skyler B Johnson, Neeraj Agarwal, Manish Kohli, Sumati Gupta, Umang Swami, and Benjamin L. Maughan. Comparing pretest video genetic education for prostate cancer patients: Do patients need assistance?
Journal of Clinical Oncology. (2022): 40:16_suppl, 5061-5061

Skyler B Johnson. Cancer Misinformation: Its Impact on Patients and Mitigation Strategies. IASLC Lung Cancer News. (published online April 2022)

Skyler B. Johnson, Matthew Parsons, Tanya Dorff, et al. Información errónea y perjudicial sobre el cáncer en Facebook y otras redes sociales: Un breve informe. J Natl Cancer Inst. 22 Jul 2021;djab141. doi: 10.1093/jnci/djab141. PMID: 34291289. Traducido por Candela Sznajderman, publicado en Boletín Fármacos: Ética y Derecho 2022; 25(1).

Samantha Greenberg, Elizabeth Woelmer, Morgan Devlin, Sara Low, Amanda Anson, Wendy Kohlmann, Bob Wong, Brock O Neil, Christopher B. Dechet, Alejandro Sanchez, Jonathan David Tward, Skyler B Johnson, Neeraj Agarwal, Manish Kohli, Sumati Gupta, Umang Swami, and Benjamin L. Maughan. Impact of pretest video genetic education in prostate cancer patients: Do patients need us? Journal of Clinical Oncology. (2022): 40:6_suppl, 68-68.

Peterson, T. Wilson, J.D. Gruhl, S. Davis, J. Olsen, M.W. Parsons, B.H. Kann, M. Watt, A.S. Fagerlin, B. Swire-Thompson, S. B. Johnson (November 2021). The Association Between Conventional Cancer Treatment History and Dissatisfaction Among Those Seeking Alternative Cancer Therapies: Insights From a Crowdfunding Platform. International Journal of Radiation Oncology, Biology, Physics, V111, Issue 3, Supplement, E344-E345.

Skyler B Johnson, MD, Matthew Parsons, MD, Tanya Dorff, MD, Meena S Moran, MD, John H Ward, MD, Stacey A Cohen, MD, Wallace Ackerley, MD, Jessica Bauman, MD, Joleen Hubbard, MD, Daniel E Spratt, MD Carma L Bylund, PhD, Briony Swire-Thompson, PhD, Tracy Onega, PhD, Laura D Scherer, PhD, Jonathan Tward, MD, PhD, Angela Fagerlin, PhD (July 2021). Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report. Journal of the National Cancer Institute, djab141.

Joseph A Miccio, Wesley J Talcott, Vikram Jairam, Henry S Park, James B Yu, Michael S Leapman, Skyler B Johnson, Martin T King, Paul L Nguyen & Benjamin H Kann (June 2021). Quantifying treatment selection bias effect on survival in comparative effectiveness of research: findings from low-risk prostate cancer patients. Prostate Cancer and Prostatic Diseases, 24, 414-422.

Ryan J. Hutten, Matthew W. Parsons, Christopher R Weil, Jonathan D. Tward, Shane Lloyed, Alejandro Sanchez, Nataniel Lester-Coll, Skyler B. Johnson (available online May 2021). Temporal Trends and Predictors in Diagnosing Pathologic Node-Positive Prostate Cancer in Clinically Node-Negative Patients. Clinical Genitourinary Cancer.

John Stuart Peterson, Deborah Plana, Danielle Sara Bitterman, Skyler B Johnson, Benjamin Harris Kann (published online May 2021). Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)-affiliated trials. Journal of Clinical Oncology, 39, no15_suppl, 1515-1515.

Matthew Parsons, MD, Shane Lloyd, MD, Skyler Johnson, MD, Courney Scaife, MD, Thomas Varghese, MD, MS, Robert Glasgow, MD, Ignacio Garrido-Laguna, MD, PhD & Randa Tao, MD (February 2021). Refusal of Local Therapy in Esophageal Cancer and Impact on Overall Survival. Annals of Surgical Oncology, 28, 663-675.

Matthew Parsons, Ryan Hutten, Ashley Khouri, Alexander Tward, Glen Morrell, John Stuart Peterson, Donald Maurice Cannon, Shane Lloyd, Skyler B Johnson (published online February 2021). The effect of maximum tumor diameter on disease control in intermediate and high-risk prostate cancer patients treated with brachytherapy boost. Journal of Clinical Oncology, 39, no. 6_suppl, 252-252.

Ryan J. Hutten, Christopher R. Weil, Jonathan D. Tward, Shane Lloyd, Skyler B. Johnson (available online Jan 2021). Patterns of Care and Treatment Outcomes in Locoregional Squamous Cell Carcinoma of the Prostate. European Urology Open Science, V23, Pages 30-33.

Peterson, John S, Swire-Thompson, Briony, Johnson, Skyler B (2020). What is the Alternative? Responding Strategically to Cancer Misinformation. Future Oncology, 16(25), 1883-1888.

Kole AJ, Park HS, Johnson SB, Kelly JR, Moran MS, Patel AA (2019). Overall Survival is Improved When DCIS Accompanies Invasive Breast Cancer. Scientific Reports, 9(1), 9934.

Johnson SB, Hung J, Kapadia N, Oh KS, Kim M, Hamstra DA (2019). Spinal Growth Patterns After Craniospinal Irradiation in Children With Medulloblastoma. Pract Radiat Oncol, 9(1), e22-e28.

Johnson SB, Park HS, Gross CP, Yu JB (2018). Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. JAMA Oncol, 4(10), 1375-1381.

Johnson SB, Park HS, Gross CP, Yu JB (2018). Use of Alternative Medicine for Cancer and Its Impact on Survival. LID - 10.1093/jnci/djx145 [doi]. J Natl Cancer Inst, 110(1).

Kann BH, Park HS, Johnson SB, Chiang VL, Yu JB (2017). Radiosurgery for Brain Metastases: Changing Practice Patterns and Disparities in the United States. J Natl Compr Canc Netw, 15(12), 1494-1502.

Johnson SB, Lester-Coll NH, Kelly JR, Kann BH, Yu JB, Nath SK (2017). Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer. Eur Urol, 72(5), 738-744.

Lester-Coll NH, Johnson S, Magnuson WJ, Goldhaber SZ, Sher DJ, D'Amico AV, Yu JB (2017). Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. LID - 10.1093/jnci/djw281 [doi]. J Natl Cancer Inst, 109(6).

Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB (2016). Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol, 121(2), 294-298.

Feng FY, Zhang Y, Kothari V, Evans JR, Jackson WC, Chen W, Johnson SB, Luczak C, Wang S, Hamstra DA (2016). MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia, 18(4), 213-22.

Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY (2016). Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy. Eur Urol, 69(1), 50-7.

Johnson SB, Jackson WC, Murgic J, Feng FY, Hamstra DA (2015). Time to Nadir PSA: Of Popes and PSA--The Immortality Bias. Am J Clin Oncol, 38(5), 465-71.

Jackson WC, Johnson SB, Feng FY, Hamstra DA (2015 Aug). Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol, 38(4), 367-72.

Hamstra DA, Johnson SB, Daignault S, Zikmund-Fisher BJ, Taylor JM, Larkin K, Wood A, Fagerlin A (2015 Jan). The impact of numeracy on verbatim knowledge of the longitudinal risk for prostate cancer recurrence following radiation therapy. Med Decis Making, 35(1), 27-36.

Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra DA (2014). Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy. Radiat Oncol, 9, 245.

Johnson S, Jackson W, Speers C, Feng F, Hamstra D (2014). A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. Pract Radiat Oncol, 4(6), 422-9.

Johnson SB, Zhou J, Jolly S, Guo B, Young L, Prisciandaro JI (2014 May-Jun). The dosimetric impact of single, dual, and triple tandem applicators in the treatment of intact uterine cancer. Brachytherapy, 13(3), 268-74.

Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng FY (2014). Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol, 4(2), 99-107.

Stenmark MH, Conlon AS, Johnson S, Daignault S, Litzenberg D, Marsh R, Ritter T, Vance S, Kazzi N, Feng FY, Sandler H, Sanda MG, Hamstra DA (2014). Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiother Oncol, 110(2), 291-7.

Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY (2013 Oct 1). Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer. Int J Radiat Oncol Biol Phys, 87(2), 275-81.

Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY (2013). Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer, 119(18), 3287-94.

Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY (2013 Jul 8). A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol, 8, 170.

Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D (2013). The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 86(3), 554-61.

Hamstra DA, Stenmark MH, Ritter T, Litzenberg D, Jackson W, Johnson S, Albrecht-Unger L, Donaghy A, Phelps L, Blas K, Halverson S, Marsh R, Olson K, Feng FY (2013). Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys, 85(5), 1246-53.